

Discovery and repurposing of artemisinin

Qiaoli Shi¹, Fei Xia¹, Qixin Wang¹, Fulong Liao¹, Qiuyan Guo (✉)¹, Chengchao Xu (✉)^{1,4}, Jigang Wang (✉)^{1,2,3,4}

¹Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China; ²Central People's Hospital of Zhanjiang, Zhanjiang 524045, China; ³Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China; ⁴Department of Geriatrics, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen People's Hospital, Shenzhen 518020, China

© Higher Education Press 2022

Abstract Malaria is an ancient infectious disease that threatens millions of lives globally even today. The discovery of artemisinin, inspired by traditional Chinese medicine (TCM), has brought in a paradigm shift and been recognized as the “best hope for the treatment of malaria” by World Health Organization. With its high potency and low toxicity, the wide use of artemisinin effectively treats the otherwise drug-resistant parasites and helps many countries, including China, to eventually eradicate malaria. Here, we will first review the initial discovery of artemisinin, an extraordinary journey that was in stark contrast with many drugs in western medicine. We will then discuss how artemisinin and its derivatives could be repurposed to treat cancer, inflammation, immunoregulation-related diseases, and COVID-19. Finally, we will discuss the implications of the “artemisinin story” and how that can better guide the development of TCM today. We believe that artemisinin is just a starting point and TCM will play an even bigger role in healthcare in the 21st century.

Keywords artemisinin; drug repurposing; cancer; inflammation; COVID-19; traditional Chinese medicine

Introduction

Malaria is a life-threatening and devastating infectious disease, affecting millions of people worldwide each year [1]. It is caused by parasites of the genus *Plasmodium* and transmitted from person to person by the *Anopheles* mosquito. According to available statistics, approximately 229 million malaria cases and 409 000 deaths were reported in 87 malaria-endemic countries worldwide in 2019, particularly in the African region that accounted for approximately 94% of the total cases, with 67% of deceased cases being children younger than 5 years of age [2].

Current antimalarial control is highly reliant on artemisinin combination therapies; however, its molecular pharmacology is not fully understood. Accumulating evidence suggests that “conventional” agents prescribed for certain diseases may be repurposed to treat other diseases [3]. For example, artemisinin and its derivatives have been tested in different types of cancers, including liver cancer, colorectal cancer, gastric cancer, ovarian cancer, lung

cancer, breast cancer, cervical cancer, and esophageal cancer [4]. Furthermore, artemisinin and its derivatives could treat and prevent inflammation and immunoregulation-related diseases, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis, and allergic diseases [5]. The potential application of artemisinin and its derivatives in coronavirus disease 2019 (COVID-19) treatment has also been recently proposed [6–8].

Herein, the discovery process of artemisinin was reported, and its use and application in different medical areas, including antitumor, anti-inflammation, and antiviral (anti-COVID-19) therapy, were discussed. The readers interested in the antimalarial effects and mechanisms of action of artemisinin should be redirected to some other recent reviews [9–11].

Discovery of artemisinin

Global Malaria Eradication Program (GMEP; 1955–1969) was launched by the World Health Organization (WHO) in 1955 to eradicate the disease. Although GMEP eliminated malaria in many countries, global eradication has not been achieved [12]. Over the years, parasites with decreased sensitivity to these approaches have gradually

Received: April 6, 2021; accepted: September 23, 2021

Correspondence: Qiuyan Guo, qyguo@icmm.ac.cn;

Chengchao Xu, ccxu@icmm.ac.cn;

Jigang Wang, jgwang@icmm.ac.cn

increased, making the global malaria epidemic control difficult. In 1967, the Chinese government launched a national project called “523” to explore new treatments for malaria. In 1969, Youyou Tu, a young scientist at the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences, was appointed as the principal investigator leading the efforts to search for new antimalarial medicines. Youyou Tu used modern science to study traditional Chinese medicine (TCM); systematically collected ancient Chinese medicine books; and examined more than 2000 herbs for internal administration and external treatment; including plants, animals, and minerals. By using mouse malaria and monkey malaria animal models, more than 200 kinds of prescriptions and 380 kinds of extracts were screened, including artemisinin. Further investigation showed that high temperature should be avoided during the process of extracting artemisinin [13]. After repeated studies were conducted, in 1971, the inhibition rate of *Artemisia annua* extract against rodent malaria and monkey malaria reached 100% through a comprehensive study on the variety, harvesting season, medicinal parts, and especially, extraction methods of *Artemisia annua* L. (Fig. 1) [14]. In 1972, the first 30 cases with malaria were successfully treated with artemisinin. In 1973, Youyou Tu’s team developed dihydroartemisinin, one of the most pharmacologically active artemisinin derivatives. In the following decades, Youyou Tu’s team and other research teams in China jointly carried out a series of work related to artemisinin, such as the three-dimensional structure and molecular formula of artemisinin and the development of other artemisinin derivatives.

In 2006, the WHO officially recommended 3 days of artemisinin-based combination therapies (ACTs) as first-line treatment in the fight against malaria [15]. Artemisinin has also shown remarkable efficacy in treating previously emerging drug-resistant insect strains [16]. In 2015,



Fig. 1 *Artemisia annua* L. in the field.

Youyou Tu was awarded the Nobel Prize in Physiology or Medicine for the discovery [17]. At present, 14 medicines for curative treatment and six medicines for chemoprevention are listed in the WHO Model List of Essential Medicines. These medicines are formulated as single compounds or in combination [18]. One of the most effective ones was based on ACTs, while the use of ACTs has become an integral part of the fight against malaria, thus forming the basis for most modern treatments [19].

Repurpose of artemisinin and its derivatives

With growing failure rates and the expensive cost of novel drug discovery, repurposing traditional therapeutic Chinese medicinal agents in the treatment of cancer or other diseases provides a very attractive alternative. Artemisinin and its derivatives have been recommended as attractive candidates for drug repositioning due to their safety and efficacy, in addition to antimalarial properties. Below, the anticancer, anti-inflammation, and anti-infectious properties of artemisinin and its derivatives were discussed (Fig. 2).

Anticancer property of artemisinin and its derivatives

The anticancer property of artemisinin was originally discovered in 1993, and then it has been widely investigated and explored [20]. Since then, growing evidence has indicated that artemisinin and its derivatives exert selective cytotoxicity towards a wide range of cancers [21,22]. A broad range of putative pathways and targets is believed to be closely implicated in regulating anticancer by artemisinin and its derivatives. Given that pathway validation is important in mechanistic study, several representative pathways and targets were described in this study to analyze the antitumor property and actions of artemisinin and its derivatives (Fig. 3).

PI3K-AKT-mTOR pathway

The PI3K-AKT-mTOR pathway is essential for developing cancer by regulating cell cycle, cellular quiescence, and cell proliferation [23]. In previous studies, artemisinin was found to activate lysosomal function and induce autophagy in HCT116 [24] and HeLa [25] cell lines by inhibiting mTOR activity. This finding is in accordance with the discovery of other research team, that is, artemisinin inhibited cell proliferation by suppression of the PI3K-AKT-mTOR pathway [26].

AMP-activated protein kinase (AMPK) pathway

AMPK has a major role in regulating growth and reprogramming metabolism. It can also regulate cellular processes, such as autophagy and cell polarity [27]. Under




Fig. 2 Repurpose of artemisinin and its derivatives.




Fig. 3 Structures and anticancer, anti-inflammatory, and immunoregulatory properties of artemisinin and its derivatives.

lowered intracellular ATP levels, AMP or ADP binds to the γ regulatory subunit of AMPK, further leading to its activation. The 172 phosphorylation of AMPK α is necessary for AMPK activation by LKB1, TAK1, and CaM KK β . Activated AMPK regulates ATP-consuming cellular events (fatty acid, cholesterol, and protein synthesis) and

ATP-generating processes (uptake and catabolism of glucose and fatty acids), and maintains cellular energy balance [27]. In addition, the AMPK pathway has been reported to be involved in tumor-specific metabolic regulation [28]. The activated AMPK in tumor cells decreases protein and lipid synthesis via downregulation

of the mTORC1 signaling pathway, thus limiting cell growth and proliferation [29].

Dihydroartemisinin has been demonstrated to induce acute myeloid leukemia (AML) cell death by regulating the proliferation and ferroptosis of AML cells through inducing AMPK/mTOR/p70S6k-mediated autophagy [30]. Moreover, artesunate was reported to induce autophagy-dependent apoptosis by activating the AMPK-mTOR-ULK1 pathway in human bladder cancer cells [31]. Artemisinin derivative SM1044 was found to be a potential treatment for diffuse large B cell lymphoma by the initiation of autophagy through activation of the CaMKK2-AMPK-ULK1 axis [32].

Signal transducer and activator of transcription 3 (STAT3) signaling

STAT3 is an important transcription factor that can promote cancer progression by hyperactivation or mutations in various solid malignancies, including melanoma or lung cancer [33]. *In vitro* experiments have suggested that dihydroartemisinin could suppress STAT3 phosphorylation and STAT3 inactivation, further leading to the downregulation of Mcl-1 and survivin and the enhancement of ABT-263-induced cytotoxicity [34]. Cancer stem cells (CSCs) possess strong invasive and metastatic capabilities. Dihydroartemisinin inhibits CSC-induced invasion and prevents metastasis in laryngeal carcinoma by suppressing STAT3 activation [35]. In addition, researchers discovered that artesunate promoted antitumor, antiproliferation, and apoptosis by suppression of IL-6-JAK-STAT signaling in a hepatocellular carcinoma rat model [36]. Moreover, artesunate potentially participated in the treatment of melanoma by inhibiting the STAT3 pathway and its target proteins [37].

JNK pathway

The JNK pathway is activated by stimuli, such as oxidative stress, when the upstream kinases are activated or the inhibitory phosphatases are inactivated [38]. This pathway inhibits cell growth and induces cell death by regulating Bcl-2 protein-mediated apoptosis [39] and ER stress-related autophagy [40]. Based on previous studies, artemisinin derivative dihydroartemisinin could induce autophagic and apoptotic cell death by producing ROS in human pancreatic tumor and myeloid leukemia through the regulation of JNK and Bcl-2 [41]. Moreover, the JNK inactivation by dihydroartemisinin derivative L-A03 (the structure could be found in Fig. 3) was reported to be responsible for the autophagy-mediated anticancer property in breast cancer [42].

NF- κ B activity

NF- κ B is regarded as an important therapeutic target due

to its ability to decrease tumor cells' sensitivity to apoptosis and enhance tumor cell growth [43]. Without stimuli, NF- κ B is kept in the cytoplasm transcriptionally inactive. However, under certain conditions, e.g., stimulation by inflammatory mediators, it is released and translocated into the nucleus, where it serves as the central mediator of the inflammatory process, an important regulator of cell proliferation and oncogenesis [44]. Previous studies found that artemisinin inhibits the NF- κ B pathway in the HCT116 colorectal cancer cell line [45]. NF- κ B and autophagy are closely involved during tumor generation and progression. For clarification of the association between them, researchers detected major targets of the above two pathways and demonstrated that dihydroartemisinin stimulates the induction of autophagy through inhibition of NF- κ B activity [46]. Moreover, artemisinin and dihydroartemisinin have been proven to be potent anticancer drugs towards epithelial ovarian cancer by inhibiting the cell cycle-related NF- κ B-signaling pathway [47]. The above findings may help improve the understanding of the underlying actions of artemisinin and its derivatives for its therapeutic anticancer property.

Endoplasmic reticulum (ER) stress

ER stress is generated by the imbalance between the ER protein folding and the ER lumen capacity. Under pathological conditions, the unfolded protein response (UPR) is further activated, resulting in apoptosis and inflammatory response to enhance tumor development [48]. Researchers recently discovered that artemisinin may inhibit non-small cell lung cancer *in vivo* and *in vitro* by triggering ER stress [49]. Artesunate has been recommended as one of the treatments for lymphoma. It could induce the specific upregulation of ER stress markers ATF-4 and DDIT3 in malignant rather than normal B cells [50]. In addition, dihydroartemisinin, as the first-generation derivative of artemisinin, has been reported to inhibit tumors by the regulation of ER stress [51].

Anti-inflammatory and immunoregulatory properties of artemisinin and its derivatives

Potential anti-inflammation and immunoregulation properties of artemisinin and its derivatives have been recently reported. Autoreactive T cell proliferation is closely involved in the pathogenesis of autoimmune diseases, such as RA and SLE [52].

As shown in Fig. 3, researchers screened new compounds for *in vitro* immunosuppressive activity for artemisinin and discovered that derivatives SM735 [53], SM934 [54], and SM905 [55] possess potent immunoregulatory properties through the regulation of T cells. In addition, artemisinin derivative SM934 remarkably inhibited IL-2-regulated proliferation and survival of activated T cells

and enhanced activated T cells into early apoptosis without trigger resting T cells [56]. Furthermore, artemisinin analog artesunate has shown the ability to significantly ameliorate RA in K/BxN mice by diminishing B cells [57]. Moreover, artemisinin derivatives also showed potential effects on RA patients. *In vitro* study demonstrated that artesunate could inhibit the generation and production of inflammatory cytokines such as IL-6, IL-8, and IL-1 β when the synovial cells (obtained from RA patients) were stimulated with TNF- α [58].

As a chronic autoimmune disease, SLE is generated when abnormal autoreactive T lymphocytes are accumulated and autoantibody against self-antigen is secreted. Artemisinin derivative SM934 remarkably lengthened the span of life and reduced the glomerulonephritis by inhibition of Th1 and Th17 responses based on the SLE model *in vivo* [59]. Furthermore, SM934 could decrease pathogenic cytokines interferon- γ and IL-10 in serum and reduce the pathogenic autoantibodies secretion and deposition in serum and kidneys to ameliorate renal injury. Dihydroartemisinin effectively improved lupus nephritis, decreased serum TNF- α level, and suppressed its production in peritoneal macrophages in a lupus BXS mouse model [60].

To sum up, artemisinin and its derivatives exert anti-inflammatory and immunoregulatory properties by inhibiting activated T cells, diminishing B cells, depressing Th1/Th17 responses, and reducing the secretion of inflammatory cytokines.

Potentiality of artemisinin and its derivatives against COVID-19

The current evidence demonstrated that “cytokine storm” contributes to COVID-19-related mortality. Some studies suggested that antimalarial agents, such as artemisinin-family drugs, may be used as an effective approach against the “cytokine storm” in patients with COVID-19 by ameliorating infection-induced acute injuries and decreasing mortality and by regulating immune cells through inhibiting the expression of cytokines IL-1 β , TNF- α , and IL-6 [61]. In Africa, five ACTs were useful in treating COVID-19 *in vitro*; among them, mefloquine-artesunate showed the best inhibition rate, as shown in Fig. 4(1–5) [62]. In China, a clinical study indicated that artemisinin-piperazine could effectively reduce the average time to reach undetectable viral RNA from 19.3 ± 2.1 days to 10.6 ± 1.1 days with mild adverse events compared with that in the control group, as shown in Fig. 4(6) [63]. Thus, artemisinin and its derivative may be used as an alternative approach for treating COVID-19 [64].

Application of artemisinin and its derivatives in health care

Strong evidence recently demonstrated the effect of

artemisinin and dihydroartemisinin on obesity. Artemisinin and dihydroartemisinin mechanistically were proven to attenuate pancreatic β -cell damage by provoking endoplasmic reticulum stress [65]. In addition, an *in vitro* study suggested that dihydroartemisinin could markedly improve skin inflammation symptoms, reduce skin injury, and inhibit mast cell infiltration [66]. Interestingly, artesunate, an important artemisinin derivative, was reported to be effective in repairing rabbit hypertrophic scar by suppressing scar formation and reducing fibroblasts and collagen synthesis [67]. Furthermore, a recent study suggested that SM934, as a water-soluble artemisinin derivative, may be used as an alternative treatment for dry eye disease with major features of dryness and irritation by reserving the structural integrity of ocular surface and inhibiting corneal and conjunctival inflammation [68]. The above evidence shed light on the broad applications of artemisinin and its derivatives in different kinds of health problems.

Enlightenment of artemisinin

With a long history, rich resources, and unique theory, TCM has high practical value in healthcare. The success of the “artemisinin story” highlights the importance of applying evidence-based medicine to explore the benefits of TCM, as recently reaffirmed by the world facing unknown infectious diseases without effective cures. In 2003, during severe acute respiratory syndrome, significant therapeutic effects were achieved following the use of TCM [69,70]. In 2009, during the H1N1 pandemic, the State Administration of TCM issued the TCM treatment plan [71]. Now, during the COVID-19 pandemic, TCM, with its proven efficacy, has been used throughout the whole process of prevention and treatment, having a critical role in the successful management of the pandemic in China [72]. Following the guidance of evidence-based medicine, TCM, artemisinin, and alike may have wide application in the 21st century.

Future perspectives

As the first-line antimalaria therapeutic strategy, artemisinin and its derivatives have saved millions of lives. However, its molecular pharmacology is still not fully understood. The outstanding pharmacological features are due to their unique mechanisms. Exact action principles and direct targets of artemisinin and its derivatives against malaria and the mechanism of action and solutions to artemisinin-resistant malaria need to be further investigated. Extended applications of artemisinin and derivatives in non-malarial areas have been investigated. Artemisinin and derivatives have shown promising application in antitumor, anti-inflammation, and antiviral (anti-COVID-19) therapy. However, the specification principles of artemisinin and derivatives in their




Fig. 4 Artemisinin and its derivatives-based combination therapies against COVID-19.

application in tumor, inflammation, and COVID-19 need to be clarified on the basis of different research models.

From the WHO's establishment of GMPE in 1955 to the release of a new global antimalaria target in 2015, the road to antimalaria has been up and down, and some regional successes have shown that eradication of malaria is completely feasible. Starting from 2017, China has not reported local primary malaria cases for 4 consecutive years and was certified malaria-free by WHO on June 30, 2021. The authors believe that the global goal of "malaria elimination" is within reach.

Artemisinin is a new starting point for the internationalization of TCM. The research ideas, processes, and achievements of artemisinin provide a guiding model for the modernization and development of TCM. At present, TCM culture should be further developed and combined with modern technology, thus making it more easily available to people worldwide.

Acknowledgements

The authors gratefully acknowledge the financial support from the National Key R&D Program of China (No. 2020YFA0908000), the National Natural Science Foundation of China (Nos. 82074098 and 82104480), the Innovation Team and Talents Cultivation Program

of National Administration of Traditional Chinese Medicine (No. ZYXCXTD-C-202002), the CACMS Innovation Fund (No. CI2021A05101), and the Fundamental Research Funds for the Central Public Welfare Research Institutes (Nos. ZZ14-YQ-050, ZZ14-YQ-051, ZZ14-YQ-059, ZZ14-YQ-060, ZZ14-ND-010, ZZ14-LFL-002, ZZ15-ND-10, ZXKT19018, and ZXKT19021).

Compliance with ethics guidelines

Qiaoli Shi, Fei Xia, Qixin Wang, Fulong Liao, Qiuyan Guo, Chengchao Xu, and Jigang Wang declare that they have no conflict of interest. This manuscript is a review article, and it does not involve a research protocol requiring approval by the relevant institutional review board or ethics committee.

References

1. Tu YY. Artemisinin—a gift from traditional Chinese medicine to the world (Nobel Lecture). *Angew Chem Int Ed Eng* 2016; 155(35): 10210–10226
2. World Health Organization. World malaria report 2020: 20 years of global progress and challenges. Geneva: World Health Organization, 2020

3. Yoshida GJ. Therapeutic strategies of drug repositioning targeting autophagy to induce cancer cell death: from pathophysiology to treatment. *J Hematol Oncol* 2017; 10(1): 67
4. Efferth T. From ancient herb to modern drug: *Artemisia annua* and artemisinin for cancer therapy. *Semin Cancer Biol* 2017; 46: 65–83
5. Ho WE, Peh HY, Chan TK, Wong WS. Artemisinins: pharmacological actions beyond anti-malarial. *Pharmacol Ther* 2014; 142(1): 126–139
6. Li G, Yuan M, Li H, Deng C, Wang Q, Tang Y, Zhang H, Yu W, Xu Q, Zou Y, Yuan Y, Guo J, Jin C, Guan X, Xie F, Song J. Safety and efficacy of artemisinin-piperazine for treatment of COVID-19: an open-label, non-randomised and controlled trial. *Int J Antimicrob Agents* 2021; 57(1): 106216
7. Gendrot M, Dufloy I, Boxberger M, Delandre O, Jardot P, Le Bideau M, Andreani J, Fonta I, Mosnier J, Rolland C, Hutter S, La Scola B, Pradines B. Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: *in vitro* inhibition of SARS-CoV-2 replication by mefloquine-artesunate. *Int J Infect Dis* 2020; 99: 437–440
8. Krishna S, Augustin Y, Wang J, Xu C, Staines HM, Platteeuw H, Kamarulzaman A, Sall A, Kremsner P. Repurposing antimalarials to tackle the COVID-19 pandemic. *Trends Parasitol* 2021; 37(1): 8–11
9. Yang J, He Y, Li Y, Zhang X, Wong YK, Shen S, Zhong T, Zhang J, Liu Q, Wang J. Advances in the research on the targets of anti-malaria actions of artemisinin. *Pharmacol Ther* 2020; 216: 107697
10. Wang J, Xu C, Liao FL, Jiang T, Krishna S, Tu Y. Suboptimal dosing triggers artemisinin partner drug resistance. *Lancet Infect Dis* 2019; 19(11): 1167–1168
11. Wang J, Xu C, Liao FL, Jiang T, Krishna S, Tu Y. A temporizing solution to “artemisinin resistance”. *N Engl J Med* 2019; 380(22): 2087–2089
12. Strategic Advisory Group on Malaria Eradication. Malaria eradication: benefits, future scenarios and feasibility. A report of the Strategic Advisory Group on Malaria Eradication. Geneva: World Health Organization, 2020
13. Ma N, Zhang Z, Liao F, Jiang T, Tu Y. The birth of artemisinin. *Pharmacol Ther* 2020; 216: 107658
14. Tu Y. The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. *Nat Med* 2011; 17(10): 1217–1220
15. World Health Organization. Guidelines for the treatment of malaria. 1st ed. Geneva: World Health Organization, 2006
16. Efferth T, Kaina B. Toxicity of the antimalarial artemisinin and its derivatives. *Crit Rev Toxicol* 2010; 40(5): 405–421
17. The Nobel Prize. The Nobel Prize in Physiology or Medicine. 2015. <https://www.nobelprize.org/prizes/medicine/2015/summary/> (accessed March 5, 2021)
18. World Health Organization. World Health Organization Model List of Essential Medicines. 21st List. Geneva: World Health Organization, 2019
19. Eastman RT, Fidock DA. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. *Nat Rev Microbiol* 2009; 7(12): 864–874
20. Sun X, Yan P, Zou C, Wong YK, Shu Y, Lee YM, Zhang C, Yang ND, Wang J, Zhang J. Targeting autophagy enhances the anticancer effect of artemisinin and its derivatives. *Med Res Rev* 2019; 39(6): 2172–2193
21. Woerdenbag HJ, Moskal TA, Pras N, Malingré TM, el-Ferally FS, Kampinga HH, Konings AW. Cytotoxicity of artemisinin-related endoperoxides to Ehrlich ascites tumor cells. *J Nat Prod* 1993; 56(6): 849–856
22. Lai HC, Singh NP, Sasaki T. Development of artemisinin compounds for cancer treatment. *Invest New Drugs* 2013; 31(1): 230–246
23. King D, Yeomanson D, Bryant HE. PI3King the lock: targeting the PI3K/Akt/mTOR pathway as a novel therapeutic strategy in neuroblastoma. *J Pediatr Hematol Oncol* 2015; 37(4): 245–251
24. Wang J, Zhang J, Shi Y, Xu C, Zhang C, Wong YK, Lee YM, Krishna S, He Y, Lim TK, Sim W, Hua ZC, Shen HM, Lin Q. Mechanistic investigation of the specific anticancer property of artemisinin and its combination with aminolevulinic acid for enhanced anticancer activity. *ACS Cent Sci* 2017; 3(7): 743–750
25. Yang ND, Tan SH, Ng S, Shi Y, Zhou J, Tan KSW, Wong WSF, Shen HM. Artesunate induces cell death in human cancer cells via enhancing lysosomal function and lysosomal degradation of ferritin. *J Biol Chem* 2014; 289(48): 33425–33441
26. Feng FB, Qiu HY. Effects of artesunate on chondrocyte proliferation, apoptosis and autophagy through the PI3K/AKT/mTOR signaling pathway in rat models with rheumatoid arthritis. *Biomed Pharmacother* 2018; 102: 1209–1220
27. Wang YS, Yu P, Wang Y, Zhang J, Hang W, Yin ZX, Liu G, Chen J, Werle KD, Quan CS, Gao H, Zeng Q, Cui R, Liang J, Ding Q, Li YL, Xu ZX. AMP-activated protein kinase protects against necroptosis via regulation of Keap1-PGAM5 complex. *Int J Cardiol* 2018; 259: 153–162
28. Carling D. AMPK signalling in health and disease. *Curr Opin Cell Biol* 2017; 45: 31–37
29. Choi YK, Park KG. Metabolic roles of AMPK and metformin in cancer cells. *Mol Cells* 2013; 36(4): 279–287
30. Du J, Wang T, Li Y, Zhou Y, Wang X, Yu X, Ren X, An Y, Wu Y, Sun W, Fan W, Zhu Q, Wang Y, Tong X. DHA inhibits proliferation and induces ferroptosis of leukemia cells through autophagy dependent degradation of ferritin. *Free Radic Biol Med* 2019; 131: 356–369
31. Zhou X, Chen Y, Wang F, Wu H, Zhang Y, Liu J, Cai Y, Huang S, He N, Hu Z, Jin X. Artesunate induces autophagy dependent apoptosis through upregulating ROS and activating AMPK-mTOR-ULK1 axis in human bladder cancer cells. *Chem Biol Interact* 2020; 331: 109273
32. Cheng C, Wang T, Song Z, Peng L, Gao M, Hermine O, Rousseaux S, Khochbin S, Mi JQ, Wang J. Induction of autophagy and autophagy-dependent apoptosis in diffuse large B-cell lymphoma by a new antimalarial artemisinin derivative, SM1044. *Cancer Med* 2018; 7(2): 380–396
33. Orlova A, Wagner C, de Araujo ED, Bajusz D, Neubauer HA, Herling M, Gunning PT, Keserü GM, Moriggl R. Direct targeting options for STAT3 and STAT5 in cancer. *Cancers (Basel)* 2019; 11(12): 1930
34. Yan X, Li P, Zhan Y, Qi M, Liu J, An Z, Yang W, Xiao H, Wu H, Qi Y, Shao H. Dihydroartemisinin suppresses STAT3 signaling and Mcl-1 and survivin expression to potentiate ABT-263-induced apoptosis in non-small cell lung cancer cells harboring EGFR or RAS mutation. *Biochem Pharmacol* 2018; 150: 72–85
35. Wang W, Sun Y, Li X, Shi X, Li Z, Lu X. Dihydroartemisinin prevents distant metastasis of laryngeal carcinoma by inactivating

- STAT3 in cancer stem cells. *Med Sci Monit* 2020; 26: e922348
36. Ilamathi M, Prabu PC, Ayyappa KA, Sivaramakrishnan V. Artesunate obliterates experimental hepatocellular carcinoma in rats through suppression of IL-6-JAK-STAT signalling. *Biomed Pharmacother* 2016; 82: 72–79
 37. Berköz M, Özkan-Yılmaz F, Özlüer-Hunt A, Krośniak M, Türkmen Ö, Korkmaz D, Keskin S. Artesunate inhibits melanoma progression *in vitro* via suppressing STAT3 signaling pathway. *Pharmacol Rep* 2021; 73(2): 650–663
 38. Zheng L, Wang C, Luo T, Lu B, Ma H, Zhou Z, Zhu D, Chi G, Ge P, Luo Y. JNK activation contributes to oxidative stress-induced parthanatos in glioma cells via increase of intracellular ROS production. *Mol Neurobiol* 2017; 54(5): 3492–3505
 39. Weston CR, Davis RJ. The JNK signal transduction pathway. *Curr Opin Cell Biol* 2007; 19(2): 142–149
 40. Ogata M, Hino S, Saito A, Morikawa K, Kondo S, Kanemoto S, Murakami T, Taniguchi M, Tanii I, Yoshinaga K, Shiosaka S, Hammarback JA, Urano F, Imaizumi K. Autophagy is activated for cell survival after endoplasmic reticulum stress. *Mol Cell Biol* 2006; 26(24): 9220–9231
 41. Wei Y, Sinha S, Levine B. Dual role of JNK1-mediated phosphorylation of Bcl-2 in autophagy and apoptosis regulation. *Autophagy* 2008; 4(7): 949–951
 42. Yao GD, Ge MY, Li DQ, Chen L, Hayashi T, Tashiro SI, Onodera S, Guo C, Song SJ, Ikejima T. L-A03, a dihydroartemisinin derivative, promotes apoptotic cell death of human breast cancer MCF-7 cells by targeting c-Jun N-terminal kinase. *Biomed Pharmacother* 2018; 105: 320–325
 43. Orłowski RZ, Baldwin AS Jr. NF- κ B as a therapeutic target in cancer. *Trends Mol Med* 2002; 8(8): 385–389
 44. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF- κ B. *J Clin Invest* 2001; 107(3): 241–246
 45. Chen X, Wong YK, Lim TK, Lim WH, Lin QS, Wang JG, Hua ZC. Artesunate activates the intrinsic apoptosis of HCT116 cells through the suppression of fatty acid synthesis and the NF- κ B pathway. *Molecules* 2017; 22(8): 1272
 46. Hu W, Chen SS, Zhang JL, Lou XE, Zhou HJ. Dihydroartemisinin induces autophagy by suppressing NF- κ B activation. *Cancer Lett* 2014; 343(2): 239–248
 47. Li B, Bu S, Sun J, Guo Y, Lai D. Artemisinin derivatives inhibit epithelial ovarian cancer cells via autophagy-mediated cell cycle arrest. *Acta Biochim Biophys Sin (Shanghai)* 2018; 50(12): 1227–1235
 48. Lin Y, Jiang M, Chen W, Zhao T, Wei Y. Cancer and ER stress: mutual crosstalk between autophagy, oxidative stress and inflammatory response. *Biomed Pharmacother* 2019; 118: 109249
 49. Xiao R, Ding C, Zhu H, Liu X, Gao J, Liu Q, Lu D, Zhang N, Zhang A, Zhou H. Suppression of asparagine synthetase enhances the antitumor potency of ART and artemalogue SOMCL-14-221 in non-small cell lung cancer. *Cancer Lett* 2020; 475: 22–33
 50. Våtsveen TK, Myhre MR, Steen CB, Wälchli S, Lingjærde OC, Bai B, Dillard P, Theodossiou TA, Holien T, Sundan A, Inderberg EM, Smeland EB, Myklebust JH, Oksvold MP. Artesunate shows potent anti-tumor activity in B-cell lymphoma. *J Hematol Oncol* 2018; 11(1): 23
 51. Dai X, Zhang X, Chen W, Chen Y, Zhang Q, Mo S, Lu J. Dihydroartemisinin: a potential natural anticancer drug. *Int J Biol Sci* 2021; 17(2): 603–622
 52. Shi C, Li H, Yang Y, Hou L. Anti-inflammatory and immunoregulatory functions of artemisinin and its derivatives. *Mediators Inflamm* 2015; 2015: 435713
 53. Zhou WL, Wu JM, Wu QL, Wang JX, Zhou Y, Zhou R, He PL, Li XY, Yang YF, Zhang Y, Li Y, Zuo JP. A novel artemisinin derivative, 3-(12- β -artemisininoxy) phenoxy succinic acid (SM735), mediates immunosuppressive effects *in vitro* and *in vivo*. *Acta Pharmacol Sin* 2005; 26(11): 1352–1358
 54. Yang ZS, Wang JX, Zhou Y, Zuo JP, Li Y. Synthesis and immunosuppressive activity of new artemisinin derivatives. Part 2: 2-[12(β or α)-dihydroartemisinomethyl(or 1'-ethyl)]phenoxypropionic acids and esters. *Bioorg Med Chem* 2006; 14(23): 8043–8049
 55. Zhang JX, Wang JX, Zhang Y, Zuo JP, Wu JM, Sui Y, Li Y. Synthesis and immunosuppressive activity of new artemisinin derivatives containing polyethylene glycol group. *Acta Pharmaceutica Sinica (Yao Xue Xue Bao)* 2006; 41(1): 65–70 (in Chinese)
 56. Hou LF, He SJ, Wang JX, Yang Y, Zhu FH, Zhou Y, He PL, Zhang Y, Yang YF, Li Y, Tang W, Zuo JP. SM934, a water-soluble derivative of artemisinin, exerts immunosuppressive functions *in vitro* and *in vivo*. *Int Immunopharmacol* 2009; 9(13–14): 1509–1517
 57. Hou L, Block KE, Huang H. Artesunate abolishes germinal center B cells and inhibits autoimmune arthritis. *PLoS One* 2014; 9(8): e104762
 58. He Y, Fan J, Lin H, Yang X, Ye Y, Liang L, Zhan Z, Dong X, Sun L, Xu H. The anti-malaria agent artesunate inhibits expression of vascular endothelial growth factor and hypoxia-inducible factor-1 α in human rheumatoid arthritis fibroblast-like synovial cell. *Rheumatol Int* 2011; 31(1): 53–60
 59. Hou LF, He SJ, Li X, Yang Y, He PL, Zhou Y, Zhu FH, Yang YF, Li Y, Tang W, Zuo JP. Oral administration of artemisinin analog SM934 ameliorates lupus syndromes in MRL/lpr mice by inhibiting Th1 and Th17 cell responses. *Arthritis Rheum* 2011; 63(8): 2445–2455
 60. Li WD, Dong YJ, Tu YY, Lin ZB. Dihydroartemisinin ameliorates lupus symptom of BXSB mice by inhibiting production of TNF- α and blocking the signaling pathway NF- κ B translocation. *Int Immunopharmacol* 2006; 6(8): 1243–1250
 61. Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine storm in COVID-19: the current evidence and treatment strategies. *Front Immunol* 2020; 11: 1708
 62. Gendrot M, Duflo I, Boxberger M, Delandre O, Jardot P, Le Bideau M, Andreani J, Fonta I, Mosnier J, Rolland C, Hutter S, La Scola B, Pradines B. Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: *in vitro* inhibition of SARS-CoV-2 replication by mefloquine-artesunate. *Int J Infect Dis* 2020; 99: 437–440
 63. Li G, Yuan M, Li H, Deng C, Wang Q, Tang Y, Zhang H, Yu W, Xu Q, Zou Y, Yuan Y, Guo J, Jin C, Guan X, Xie F, Song J. Safety and efficacy of artemisinin-piperazine for treatment of COVID-19: an open-label, non-randomised and controlled trial. *Int J Antimicrob Agents* 2021; 57(1): 106216
 64. Krishna S, Augustin Y, Wang J, Xu C, Staines HM, Platteeuw H, Kamarulzaman A, Sall A, Kremsner P. Repurposing antimalarials to tackle the COVID-19 pandemic. *Trends Parasitol* 2021; 37(1): 8–11
 65. Chen K, Hua H, Zhu Z, Wu T, Jia Z, Liu Q. Artemisinin and

- dihydroartemisinin promote β -cell apoptosis induced by palmitate via enhancing ER stress. *Apoptosis* 2020; 25(3–4): 192–204
66. Xue X, Dong Z, Deng Y, Yin S, Wang P, Liao Y, Hu G, Chen Y. Dihydroartemisinin alleviates atopic dermatitis in mice by inhibiting mast cell infiltration. *J South Med Univ (Nan Fang Yi Ke Da Xue Xue Bao)* 2020; 40(10): 1480–1487 (in Chinese)
67. Nong X, Rajbanshi G, Chen L, Li J, Li Z, Liu T, Chen S, Wei G, Li J. Effect of artesunate and relation with TGF- β 1 and SMAD3 signaling on experimental hypertrophic scar model in rabbit ear. *Arch Dermatol Res* 2019; 311(10): 761–772
68. Yang FM, Fan D, Yang XQ, Zhu FH, Shao MJ, Li Q, Liu YT, Lin ZM, Cao SQ, Tang W, He SJ, Zuo JP. The artemisinin analog SM934 alleviates dry eye disease in rodent models by regulating TLR4/NF- κ B/NLRP3 signaling. *Acta Pharmacol Sin* 2021; 42(4): 593–603
69. Liu J, Manheimer E, Shi Y, Gluud C. Chinese herbal medicine for severe acute respiratory syndrome: a systematic review and meta-analysis. *J Altern Complement Med* 2004; 10(6): 1041–1051
70. World Health Organization. SARS: clinical trials on treatment using a combination of traditional Chinese medicine and Western medicine. Geneva: World Health Organization, 2004
71. National Administration of Traditional Chinese Medicine. The Traditional Chinese Medicine Prevention Program of Influenza A (H1N1) (2009). National Administration of Traditional Chinese Medicine, 2009 (in Chinese)
72. Luo H, Tang QL, Shang YX, Liang SB, Yang M, Robinson N, Liu JP. Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs. *Chin J Integr Med* 2020; 26(4): 243–250